Logo image of ARCT

ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Fundamental Analysis

NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD

16.05  +0.25 (+1.58%)

After market: 15.7 -0.35 (-2.18%)

Fundamental Rating

4

Overall ARCT gets a fundamental rating of 4 out of 10. We evaluated ARCT against 572 industry peers in the Biotechnology industry. ARCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARCT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ARCT has reported negative net income.
In the past year ARCT has reported a negative cash flow from operations.
ARCT had negative earnings in 4 of the past 5 years.
ARCT had negative operating cash flow in 4 of the past 5 years.
ARCT Yearly Net Income VS EBIT VS OCF VS FCFARCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

ARCT has a better Return On Assets (-16.90%) than 80.35% of its industry peers.
With an excellent Return On Equity value of -23.92%, ARCT belongs to the best of the industry, outperforming 82.48% of the companies in the same industry.
Industry RankSector Rank
ROA -16.9%
ROE -23.92%
ROIC N/A
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
ARCT Yearly ROA, ROE, ROICARCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCT Yearly Profit, Operating, Gross MarginsARCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

ARCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ARCT has more shares outstanding
The number of shares outstanding for ARCT has been increased compared to 5 years ago.
There is no outstanding debt for ARCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARCT Yearly Shares OutstandingARCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ARCT Yearly Total Debt VS Total AssetsARCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that ARCT is in the distress zone and has some risk of bankruptcy.
ARCT has a better Altman-Z score (1.34) than 68.85% of its industry peers.
ARCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.34
ROIC/WACCN/A
WACC10.77%
ARCT Yearly LT Debt VS Equity VS FCFARCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.76 indicates that ARCT has no problem at all paying its short term obligations.
ARCT has a Current ratio of 4.76. This is comparable to the rest of the industry: ARCT outperforms 51.86% of its industry peers.
A Quick Ratio of 4.76 indicates that ARCT has no problem at all paying its short term obligations.
ARCT's Quick ratio of 4.76 is in line compared to the rest of the industry. ARCT outperforms 53.45% of its industry peers.
Industry RankSector Rank
Current Ratio 4.76
Quick Ratio 4.76
ARCT Yearly Current Assets VS Current LiabilitesARCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

ARCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -159.84%.
The Revenue for ARCT has decreased by -45.85% in the past year. This is quite bad
ARCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 60.22% yearly.
EPS 1Y (TTM)-159.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.38%
Revenue 1Y (TTM)-45.85%
Revenue growth 3Y159.91%
Revenue growth 5Y60.22%
Sales Q2Q%-7.68%

3.2 Future

Based on estimates for the next years, ARCT will show a very strong growth in Earnings Per Share. The EPS will grow by 58.76% on average per year.
Based on estimates for the next years, ARCT will show a very strong growth in Revenue. The Revenue will grow by 34.31% on average per year.
EPS Next Y-135.59%
EPS Next 2Y-39.51%
EPS Next 3Y40.06%
EPS Next 5Y58.76%
Revenue Next Year0.98%
Revenue Next 2Y2.83%
Revenue Next 3Y25.12%
Revenue Next 5Y34.31%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ARCT Yearly Revenue VS EstimatesARCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
ARCT Yearly EPS VS EstimatesARCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCT Price Earnings VS Forward Price EarningsARCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCT Per share dataARCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

ARCT's earnings are expected to grow with 40.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.51%
EPS Next 3Y40.06%

More info and screens

0

5. Dividend

5.1 Amount

ARCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCTURUS THERAPEUTICS HOLDIN

NASDAQ:ARCT (2/4/2025, 8:27:05 PM)

After market: 15.7 -0.35 (-2.18%)

16.05

+0.25 (+1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners93.2%
Inst Owner Change-0.7%
Ins Owners1.37%
Ins Owner Change-0.33%
Market Cap434.79M
Analysts85.88
Price Target70.72 (340.62%)
Short Float %20.34%
Short Ratio12.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)69.89%
Min EPS beat(2)60.74%
Max EPS beat(2)79.04%
EPS beat(4)4
Avg EPS beat(4)56.42%
Min EPS beat(4)17.53%
Max EPS beat(4)79.04%
EPS beat(8)7
Avg EPS beat(8)347.67%
EPS beat(12)10
Avg EPS beat(12)237.61%
EPS beat(16)11
Avg EPS beat(16)170.2%
Revenue beat(2)2
Avg Revenue beat(2)68.47%
Min Revenue beat(2)11.64%
Max Revenue beat(2)125.3%
Revenue beat(4)3
Avg Revenue beat(4)59.34%
Min Revenue beat(4)-11.98%
Max Revenue beat(4)125.3%
Revenue beat(8)6
Avg Revenue beat(8)69.98%
Revenue beat(12)8
Avg Revenue beat(12)161.24%
Revenue beat(16)8
Avg Revenue beat(16)112.68%
PT rev (1m)0%
PT rev (3m)0.32%
EPS NQ rev (1m)7.97%
EPS NQ rev (3m)-291.85%
EPS NY rev (1m)1.84%
EPS NY rev (3m)26.35%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-39.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.71
P/FCF N/A
P/OCF N/A
P/B 1.66
P/tB 1.66
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.22
OCFYN/A
SpS5.92
BVpS9.67
TBVpS9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.9%
ROE -23.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.91%
ROA(5y)-20.7%
ROE(3y)-32.17%
ROE(5y)-43.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.89%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.76
Quick Ratio 4.76
Altman-Z 1.34
F-Score3
WACC10.77%
ROIC/WACCN/A
Cap/Depr(3y)296.63%
Cap/Depr(5y)241.64%
Cap/Sales(3y)11%
Cap/Sales(5y)11.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-159.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.38%
EPS Next Y-135.59%
EPS Next 2Y-39.51%
EPS Next 3Y40.06%
EPS Next 5Y58.76%
Revenue 1Y (TTM)-45.85%
Revenue growth 3Y159.91%
Revenue growth 5Y60.22%
Sales Q2Q%-7.68%
Revenue Next Year0.98%
Revenue Next 2Y2.83%
Revenue Next 3Y25.12%
Revenue Next 5Y34.31%
EBIT growth 1Y-230.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.16%
EBIT Next 3Y-29.7%
EBIT Next 5YN/A
FCF growth 1Y64.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.81%
OCF growth 3YN/A
OCF growth 5YN/A